Faithward Advisors’s Amicus Therapeutics FOLD Stock Holding History

Faithward Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,420	Closed	-$82.6K	–	308
2025 Q2	$82.6K	Buy	+14,420	New	+$93.1K	0.01%	263
2024 Q3	–	Sell	-281,659	Closed	-$2.79M	–	283
2024 Q2	$2.79M	Buy	281,659 +8,151	+3%	+$83.7K	0.51%	61
2024 Q1	$3.22M	Buy	273,508 +2,515	+0.9%	+$32.2K	0.58%	53
2023 Q4	$3.44M	Sell	270,993 -1,180	-0.4%	-$13.4K	0.76%	40
2023 Q3	$2.8M	Sell	272,173 -6,488	-2%	-$83.7K	0.68%	44
2023 Q2	$3.74M	Sell	278,661 -8,389	-3%	-$99.5K	0.86%	32
2023 Q1	$3.35M	Sell	287,050 -28,756	-9%	-$354K	0.76%	35
2022 Q4	$3.86M	Sell	315,806 -413	-0.1%	-$4.65K	0.84%	40
2022 Q3	$3.3M	Buy	+316,219	New	+$3.52M	0.78%	41

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Faithward Advisors's FOLD Position: Q3 2025 in Review

Faithward Advisors sold out of Amicus Therapeutics (FOLD) in Q3 2025, closing a stake of 14,420 shares — an estimated $82.6K sold.

Faithward Advisors first reported a position in FOLD in Q3 2022 and held it in 9 quarters. The position peaked at $3.86M in Q4 2022. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

Faithward Advisors reported no remaining Amicus Therapeutics position as of Q3 2025 after selling out during the quarter.
Faithward Advisors sold 14,420 Amicus Therapeutics shares in Q3 2025, an estimated $82.6K.
Faithward Advisors first reported a position in Amicus Therapeutics in Q3 2022 and held it in 9 quarters.
Faithward Advisors's Amicus Therapeutics position peaked at $3.86M in Q4 2022.
287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on Faithward Advisors's 13F filing for Q3 2025, filed 19 Nov 2025.